Scarica l'app Stockscreener
1.93
0.52%
0.01
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché BJDX Giù?
Forum
Previsione
Frazionamento azionario
Bluejay Diagnostics Inc Borsa (BJDX) Ultime notizie
Bluejay Diagnostics (BJDX) Q4 2023 Earnings: Deeper-Than-Expected Losses as Development Spending Weighs on ResultsEarnings Stability Report - Newser
BJDX SEC FilingsBluejay Diagnostics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BJDX Stock Price, Quote & Chart | BLUEJAY DIAGNOSTICS INC (NASDAQ:BJDX) - ChartMill
Bluejay Diagnostics director Svetlana Dey buys $25,000 in common stock By Investing.com - Investing.com Nigeria
Bluejay Diagnostics CEO Indranil Dey purchases $25,000 stock By Investing.com - Investing.com Australia
Bluejay Diagnostics director Fred S Zeidman buys $25,000 in shares - Investing.com UK
Bluejay Diagnostics director Douglas Wurth buys $25,000 in stock - Investing.com
Bluejay Diagnostics director Fred S Zeidman buys $25,000 in shares By Investing.com - Investing.com Nigeria
Bluejay Diagnostics director Douglas Wurth buys $25,000 in stock By Investing.com - Investing.com Nigeria
Bluejay Diagnostics director Donald Chase buys $25,000 in common stock - Investing.com
Bluejay Diagnostics CEO Indranil Dey purchases $25,000 stock - Investing.com
Bluejay Diagnostics director Svetlana Dey buys $25,000 in common stock - Investing.com India
Director Wurth Douglas Clark boosts Bluejay Diagnostics (BJDX) stake in $2 private share purchase - Stock Titan
Bluejay Diagnostics (NASDAQ: BJDX) CEO adds 12,500 shares in private placement - Stock Titan
Bluejay Diagnostics (BJDX) director buys 12,500 shares at $2 - Stock Titan
Director Fred S. Zeidman buys 12,500 Bluejay Diagnostics (BJDX) shares at $2.00 - Stock Titan
Bluejay Diagnostics (BJDX) director buys 12,500 shares in placement - Stock Titan
[SCHEDULE 13G/A] Bluejay Diagnostics, Inc. Amended Passive Investment Disclosure - Stock Titan
BJDX Stock Chart | BLUEJAY DIAGNOSTICS INC (NASDAQ:BJDX) - ChartMill
TradingKey - TradingKey
Bluejay Diagnostics Provides First Quarter 2026 Corporate Update - The Manila Times
Bluejay Diagnostics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Bluejay fixes sepsis test production issues, keeps 510(k) plan in view - Stock Titan
Bluejay Diagnostics (NASDAQ: BJDX) Q1 loss highlights urgent $20M funding need - Stock Titan
Bluejay Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Bluejay Diagnostics (NASDAQ: BJDX) details Q1 2026 cash and sepsis test progress - Stock Titan
Bluejay Diagnostics advances clinical trials and manufacturing for sepsis test in Q1 2026. - Pluang
Bluejay Diagnostics (NASDAQ: BJDX) seeks reverse split and major stock plan expansion - Stock Titan
BJDX Technical Analysis | Trend, Signals & Chart Patterns | BLUEJAY DIAGNOSTICS INC (NASDAQ:BJDX) - ChartMill
Bluejay Diag (BJDX) Innovation Pipeline | Q4 2023: Profit DisappointsForward EPS - Newser
BJDX Ownership | BLUEJAY DIAGNOSTICS INC (NASDAQ:BJDX) - ChartMill
Why Is Bluejay Diagnostics, Inc. (BJDX) Stock Down Today? - Meyka
Board seeks flexible reverse split, plan increase at Bluejay Diagnostics (NASDAQ: BJDX) - Stock Titan
Is Bluejay Diag (BJDX) stock risky (Slight Dip) 2026-04-20Social Flow Trades - Cổng thông tin điện tử Tỉnh Sơn La
bjdx stock: Bluejay Diagnostics Overview - Bitget
Aug Summary: How is Bluejay Diagnostics Inc managing supply chain issues2026 Technical Patterns & Growth Focused Entry Reports - baoquankhu1.vn
Macro Review: Is Bluejay Diagnostics Inc gaining market share2026 Trading Recap & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Bluejay Diagnostics Nears Completion of SYMON-II Clinical Trial with 624 Patient Enrollments for Symphony IL-6 Sepsis Test - Minichart
Bluejay Nears Completion of Pivotal SYMON-II Sepsis Trial - TipRanks
SYMON-II sepsis trial nears full enrollment at Bluejay (NASDAQ: BJDX) - Stock Titan
Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial - Bitget
Bluejay Diagnostics, Inc. Announces Completion Of 624 Patient Enrollments In Symon-Ii Pivotal Clinical Trial - TradingView — Track All Markets
Bluejay Diagnostics Achieves Milestone with 624 Patients Enrolled in Pivotal SYMON-II Trial for IL-6 Testing in Sepsis Management - Quiver Quantitative
BJDX Technical Analysis & Stock Price Forecast - Intellectia AI
Are insiders buying or selling Bluejay Diag (BJDX) Stock | Price at $1.95, Up 3.17%Investment Community Signals - Newser
Volume Recap: Why is Bluejay Diagnostics Inc stock going down2026 Pullback Review & Weekly Top Performers Watchlists - baoquankhu1.vn
Analyst Upgrade: How is Bluejay Diagnostics Inc managing supply chain issuesNew Guidance & Real-Time Buy Zone Alerts - baoquankhu1.vn
BJDX PE Ratio & Valuation, Is BJDX Overvalued - Intellectia AI
Bluejay Diagnostics, Inc. Enters Securities Purchase Agreement for $25,000 Private Placement of Common Stock - Minichart
Bluejay Diagnostics Announces Insider-Funded Private Stock Placement - TipRanks
Bluejay Diagnostics completes $125,000 private placement with board members - Investing.com
Bluejay Diagnostics Raises $125,000 in Insider Private Placement at $2.00 Per Share - tradingview.com
0.32%
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):